ISDA

Entry Detail

PDB ID:

3VTD

Keywords:

HORMONE RECEPTOR

Title:

Crystal structure of rat vitamin D receptor bound to a partial agonist 26-adamantyl-23-yne-19-norvitammin D ADTK4

Biological Source:

Source Organism:

Rattus norvegicus,

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2012-05-26

Release Date:

2013-06-12

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.70 Å

R-Value Free:

0.27

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Vitamin D3 receptor
Chain IDs:A
Chain Length:271
Number of Molecules:1
Biological Source:Rattus norvegicus

UniProt ID:P13053 Pfam ID:PF00104

Polymer Type:polypeptide(L)
Description:COACTIVATOR PEPTIDE DRIP
Chain IDs:B
Chain Length:13
Number of Molecules:1
Biological Source:

Ligand Molecules

TKD

Primary Citation

Combination of Triple Bond and Adamantane Ring on the Vitamin D Side Chain Produced Partial Agonists for Vitamin D Receptor.

Kudo, T, Ishizawa, M, Maekawa, K, Nakabayashi, M, Watarai, Y, Uchida, H, Tokiwa, H, Ikura, T, Ito, N, Makishima, M, Yamada, S.Show

J.Med.Chem. ? ? ? (2014)

PMID: 24773565 DOI: 10.1021/jm401989c

Abstact

Vitamin D receptor (VDR) ligands are therapeutic agents that are used for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism and have immense potential as therapeutic agents for autoimmune diseases, cancers, and cardiovascular diseases. However, the major side effect of VDR ligands, the development of hypercalcemia, limits their expanded use. To develop tissue-selective VDR modulators, we have designed vitamin D analogues with an adamantane ring at the side chain terminal, which would interfere with helix 12, the activation function 2, and modulate the VDR potency. Here we report 25- or 26-adamantyl-23,23,24,24-tetradehydro-19-norvitamin D derivatives (ADTK1-4, 4b,a and 5a,b). These compounds showed high VDR affinities (90% at maximum), partial agonistic activities (EC50 10(-9)-10(-8) M with 40-80% efficacy) in transactivation, and tissue-selective activity in target gene expressions. We investigate the structure-activity relationships of these compounds on the basis of their X-ray crystal structures.

Legend

Protein

Chemical

Disease

Primary Citation of related structures